心力衰竭中的交感-上腺机制:对病理生理学的新见解
Xiaojun Du1,2
1Faculty of Physiology and Pathophysiology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, 76 West Yanta Road, Xi'an 710061, Shaanxi, China.
Medical review (2021)
|September 19, 2023
概括
在心力衰竭 (HF) 中,交感神经系统的激活通过β-上腺素受体 (βAR) 信号驱动不良的心脏重塑. 本综述详细介绍了理解同情βAR机制及其对HF治疗影响的近期进展.
科学领域:
- 心血管生理学心血管生理学
- 神经心脏病学 神经心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 交感神经系统 (SNS) 在心力衰竭 (HF) 中被激活以保持血液动力学稳定性.
- 然而,持续的SNS激活和β-上腺素受体 (βAR) 信号传递有助于心肌重塑,功能障碍和高频率患者的电动不稳定性.
- 这种同情-βAR轴是HF的关键病理生理机制,也是β-阻断疗法的目标.
研究的目的:
- 审查最近的研究进展,以了解心脏衰竭中的交感-上腺体机制.
- 要突出特定上腺素受体 (β2AR,α1AR) 和β1AR自身抗体在高血压中的作用.
- 讨论βAR信号传递,神经免疫相互作用和高频率中交感神经重塑的新方面.
主要方法:
- 本文是一个综述,综合了各种关于高频患者交感上腺系统研究的最新发现.
- 它整合了关于心脏受体功能,自身抗体重要性,G蛋白独立通路和神经免疫细胞相互作用的研究.
- 它还检查了交感神经重塑,前突触α2AR调节和基于设备的神经调节策略.
主要成果:
- 最近的研究已经阐明了心脏β2AR和α1AR在心脏衰竭中的复杂作用.
- 越来越多地认识到β1AR自身抗体和通过G蛋白独立通路的βAR信号的意义.
- 免疫细胞和纤维细胞的交感βAR调节,以及交感神经重塑和神经调节,是最近进展的关键领域.
结论:
- 了解HF中复杂的交感-上腺功能机制对于开发有效的治疗策略至关重要.
- 本次审查强调了重要的知识差距和未来高频研究突破的有前途领域.
- 针对交感上腺系统的特定组件,有可能为心力衰竭提供新的治疗方法.
更多相关视频
12:43Rodent Working Heart Model for the Study of Myocardial Performance and Oxygen Consumption
Published on: August 16, 2016
20.3K
06:30Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats
Published on: September 11, 2018
7.9K
相关概念视频
01:29Heart Failure II: Pathophysiology
15
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
15
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
460
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
460
01:22Heart Failure Drugs: β-Blockers
363
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
363
01:22Heart Failure Drugs: Diuretics
418
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
418
01:27Heart Failure I: Introduction
14
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
14